Literature DB >> 16759165

Chemotherapy in the treatment of malignant gliomas.

Jennifer I Stern1, Jeffrey J Raizer.   

Abstract

Malignant gliomas are one of the most difficult tumors to treat, with only modest advances being made in the past few decades. Surgery and radiation have had the greatest impact, increasing survival. Chemotherapy modestly increases survival. The use of chemotherapy in the treatment of malignant gliomas is the focus of this paper and the more commonly used agents at diagnosis and relapse are reviewed. Since most patients fail first-, second- and even third-line agents that are commercially available, some of the more relevant new biological compounds will also be discussed. As treatments for brain tumors evolve, it is likely that optimal therapies will come from combination therapies that incorporate target-specific and chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759165     DOI: 10.1586/14737140.6.5.755

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  5 in total

Review 1.  Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.

Authors:  Randy S D'Amico; Deepak Khatri; Noah Reichman; Nitesh V Patel; Tamika Wong; Sherese R Fralin; Mona Li; Jason A Ellis; Rafael Ortiz; David J Langer; John A Boockvar
Journal:  J Neurooncol       Date:  2020-02-19       Impact factor: 4.130

2.  Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence.

Authors:  Jingwei Xue; Zekai Zhao; Lei Zhang; Lingjing Xue; Shiyang Shen; Yajing Wen; Zhuoyuan Wei; Lu Wang; Lingyi Kong; Hongbin Sun; Qineng Ping; Ran Mo; Can Zhang
Journal:  Nat Nanotechnol       Date:  2017-06-19       Impact factor: 39.213

3.  Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy.

Authors:  Hetal Pandya; Waldemar Debinski
Journal:  BioDrugs       Date:  2012-08-01       Impact factor: 5.807

4.  Rehabilitation in primary and metastatic brain tumours: impact of functional outcomes on survival.

Authors:  V Tang; M Rathbone; J Park Dorsay; S Jiang; D Harvey
Journal:  J Neurol       Date:  2008-05-30       Impact factor: 4.849

5.  Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery.

Authors:  Wenyan Hao; Yuexin Cui; Yueyue Fan; Mengyu Chen; Guobao Yang; Yuli Wang; Meiyan Yang; Zhiping Li; Wei Gong; Yang Yang; Chunsheng Gao
Journal:  J Nanobiotechnology       Date:  2021-11-20       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.